FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to a haemostatic agent. Haemostatic agent is a composition of solid thrombin and native hyaluronic acid, its water-soluble salt or its/solvate salt, thrombin content in it is not less than 0.01 IU/cm2 and not more than 0.06 IU/cm2.
EFFECT: agent described above is biocompatible and bioresorbable, does not swell and provides a minimum period of time to achieve haemostasis.
2 cl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
HAEMOSTASIS COMPOSITION INCLUDING A MATRIX BASED ON A CROSS-LINKING HYALURONIC ACID DERIVATIVE | 2017 |
|
RU2740191C2 |
HEMOSTATIC COMPOSITION COMPRISING HYALURONIC ACID | 2005 |
|
RU2369408C2 |
HAEMOSTATIC COMPOSITION CONTAINING HYALURONIC ACID | 2009 |
|
RU2486921C2 |
HEMOSTATIC AGENT | 2019 |
|
RU2709816C1 |
METHOD FOR COMMERCIAL PRODUCTION OF THROMBIN | 2010 |
|
RU2457248C2 |
HEMOSTATIC BIOLOGICALLY ABSORBED DEVICE WITH POLYETHYLENE GLYCOL AS BINDING SUBSTANCE | 2012 |
|
RU2627426C2 |
HAEMOSTATIC AGENT | 2023 |
|
RU2826361C1 |
HEMOSTATIC BIOLOGICALLY ABSORBABLE DEVICE WITH POLYETHYLENE GLYCOL AS A BINDING SUBSTANCE | 2012 |
|
RU2646728C1 |
METHOD FOR OBTAINING A LIOPHILIZED PREPARATION OF AN ACTIVATED PROTROMBIN COMPLEX HAVING VIII-SHUNTING ACTIVITY FACTOR | 2017 |
|
RU2648517C1 |
PLANT GROWTH REGULATOR | 2021 |
|
RU2759761C1 |
Authors
Dates
2025-01-21—Published
2023-12-24—Filed